Menu
Developing
breakthrough
treatment for dyskinesia
PolyCore is committed to applying novel science to
give patients with Parkinson’s Disease and other CNS
disorders better quality of life.
Our lead compound, PCT-3012, targets dyskinesia and cognitive impairment associated with neurodegenerative disorders and is currently in preclinical studies for treatment of motor symptoms and dyskinesia in patients with early- to mid-stage Parkinson’s Disease (PD).
Advancing PCT-3012
for Levodopa-Induced Dyskinesia
PolyCore’s PCT-3012 novel dopamine D3 receptor agonist is designed to modify how L-dopa works instead of negating its effects, to improve motor symptoms without the development of tolerance, dyskinesia or impulsive behaviors.
Did You Know?
Levodopa (L-dopa), discovered in the late 1960s, is still the gold standard gold standard for treating PD symptoms today.
After 4-10 years of treatment, ~50% of patients experience “L-dopa induced dyskinesia” (LID).
LID manifests as abnormal involuntary body movements that can interfere with daily life.
The Latest from PolyCore
A Promising Pipeline
How can PCT-3012’s differentiated mechanism of action address other CNS disorders?
